vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) reported Q3 2025 results and operational updates on Nov 6, 2025. Key developments include randomizing the first patient in the Phase 3 CATT1 trial (Aug 2025) and expecting topline CATT1 data in H2 2026. The company completed an $80 million private placement (Sep 2025) to fund CATT1 and program development. Cash was $98.5 million at September 30, 2025 versus $36.7 million at December 31, 2024. R&D expense for Q3 2025 was $7.0 million (Q3 2024: $3.2M); G&A was $3.7 million (Q3 2024: $3.3M). Q3 net loss attributable to vTv shareholders was $8.7 million or $1.08 per basic share. A U.S. patent covering crystalline salts and co-crystals of cadisegliatin was allowed with exclusivity expected through 2041.

Positive

• Raised $80.0 million private placement (September 2025)
• Cash balance of $98.5 million at September 30, 2025
• U.S. patent allowance through 2041 for crystalline cadisegliatin forms
• First patient randomized in Phase 3 CATT1 (August 2025)

Negative

• Net loss of $8.7 million in Q3 2025 (basic loss per share $1.08)
• R&D expense rose to $7.0 million in Q3 2025 from $3.2 million
• Total liabilities increased to $28.951 million at September 30, 2025

Insights

Clinical Development Expert

Phase 3 progress, a patent allowance, and funded operations position cadisegliatin development through topline CATT1 data in second half of 2026.

The company randomized its first participant in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin and expects topline CATT1 data in second half of 2026. The announcement also notes a newly allowed U.S. patent for crystalline salt and co‑crystal forms of cadisegliatin with term through 2041, which provides composition‑of‑matter coverage for those forms.

Key dependencies and risks are explicit: the program’s forward value hinges on successful CATT1 topline outcomes and regulatory steps not disclosed here. Watch the second half of 2026 topline readout and any subsequent disclosures about primary endpoint achievement, safety signals, and regulatory plans; those items will determine clinical and regulatory trajectory within the next 6–12 months.

Financial Strategy Expert

An $80 million private placement materially strengthens liquidity and funds Phase 3 work, while quarterly results show higher R&D spend and a deeper net loss.

The company reports cash of $98.5 million as of September 30, 2025, up from $36.7 million at year end, driven by an $80 million private placement intended to fund the CATT1 Phase 3 trial. R&D expenses rose to $7.0 million for the quarter from $3.2 million a year earlier, and net loss widened to $8.7 million for the quarter versus $4.8 million previously.

Near‑term monitoring items include cash runway relative to ongoing trial spend, milestone accruals tied to the Novo Nordisk license noted as increasing indirect costs, and the timing of the CATT1 topline in second half of 2026. Expect clearer financial implications after the topline readout and any further financings or milestones within the next 6–12 months.

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 

$80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion

Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041

HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent corporate developments.

“The third quarter saw a series of meaningful achievements,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “During the quarter, we randomized our first patient in the Phase 3 CATT1 trial, expanded our U.S. patent estate for cadisegliatin, and successfully completed an $80 million private placement financing with leading healthcare investors. With a strengthened balance sheet, we are positioned to continue advancing our cadisegliatin program and remain on track to report topline results from the CATT1 trial in the second half of 2026.”

Recent Company Highlights

• Strengthened Balance Sheet with $80 Million Private Placement. In September 2025, vTv announced the successful closing of an $80 million private placement with new and existing healthcare investors as well as the T1D Fund. The proceeds are expected to fund the ongoing CATT1 Phase 3 trial and continued development of the cadisegliatin program for the treatment of T1D.
• First Study Participant Randomized in Cadisegliatin Phase 3 Trial. In August 2025, vTv Therapeutics announced that the first study participant was randomized in the Company’s CATT1 Phase 3 trial evaluating cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D. Topline data from the study is expected in the second half of 2026.
• Patent Allowance for Crystalline Salt Form of Cadisegliatin. In August 2025, the United States Patent and Trademark Office allowed claims for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041.
  
  

Third Quarter 2025 Financial Results

• Cash Position: The Company’s cash position as of September 30, 2025, was $98.5 million compared to $36.7 million as of December 31, 2024.
• Research & Development (R&D) Expenses: R&D expenses were $7.0 million and $3.2 million in each of the three months ended September 30, 2025, and 2024, respectively. The increase reflects higher spending on cadisegliatin, and other projects and higher indirect costs primarily related to the Novo Nordisk license milestone accrual and increases in payroll and share-based expenses.
• General & Administrative (G&A) Expenses: G&A expenses were $3.7 million and $3.3 million for each of the three months ended September 30, 2025, and 2024, respectively. The increase was primarily due to increases in payroll and legal expenses.
• Other (Expense)/Income, Net: Other expense for the three months ended September 30, 2025, was immaterial. Other income of $0.2 million for the three months ended September 30, 2024, was driven by gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock.
• Net Loss: Net loss attributable to vTv shareholders for the three months ended September 30, 2025, was $8.7 million or $1.08 per basic share. Net loss attributable to vTv shareholders for the comparable period a year ago was $4.8 million or $0.88 per basic share.
  
  

vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands)
	September 30, 2025				December 31, 2024
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	98,504			$	36,746
Prepaid expenses		840				1,192
Other current assets		112				175
Total current assets		99,456				38,113
Property and equipment, net		14				28
Operating lease right-of-use assets		24				125
Total assets	$	99,494			$	38,266
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	9,803			$	5,027
Current portion of operating lease liabilities		32				169
Current portion of notes payable		328				—
Total current liabilities		10,163				5,196
Contract liabilities, net of current portion		18,669				18,669
Warrant liability, related party		37				57
Warrant liability		82				43
Total liabilities		28,951				23,965
Commitments and contingencies
Stockholders’ equity:
Class A Common Stock		39				26
Class B Common Stock		—				6
Additional paid-in capital		390,058				311,885
Accumulated deficit		(319,554	)			(299,718	)
Total stockholders’ equity attributable to vTv Therapeutics Inc.		70,543				12,199
Noncontrolling interest		—				2,102
Total stockholders’ equity		70,543				14,301
Total liabilities and stockholders’ equity	$	99,494			$	38,266

vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
	(Unaudited)								(Unaudited)
Revenue	$	—			$	—			$	—			$	1,000
Operating expenses:
Research and development		7,020				3,224				13,953				9,312
General and administrative		3,679				3,282				10,970				10,976
Total operating expenses		10,699				6,506				24,923				20,288
Operating loss		(10,699	)			(6,506	)			(24,923	)			(19,288	)
Interest income		399				504				1,005				1,136
Interest expense		(5	)			—				(5	)			—
Other (expense)/income, net		(40	)			162				(19	)			(16	)
Loss before income taxes and noncontrolling interest		(10,345	)			(5,840	)			(23,942	)			(18,168	)
Income tax provision		—				—				—				100
Net loss before noncontrolling interest		(10,345	)			(5,840	)			(23,942	)			(18,268	)
Less: net loss attributable to noncontrolling interest		(1,647	)			(1,057	)			(4,106	)			(3,440	)
Net loss attributable to vTv Therapeutics Inc.	$	(8,698	)		$	(4,783	)		$	(19,836	)		$	(14,828	)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$	(8,698	)		$	(4,783	)		$	(19,836	)		$	(14,828	)
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted	$	(1.08	)		$	(0.88	)		$	(2.80	)		$	(2.70	)
Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted		8,055,940				5,456,307				7,080,681				5,498,479

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Forward-Looking Statement

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

What is vTv Therapeutics' (VTVT) timeline for Phase 3 CATT1 topline results?

vTv expects topline Phase 3 CATT1 results in the second half of 2026.

How much did vTv Therapeutics (VTVT) raise in the September 2025 private placement?

vTv completed an $80 million private placement in September 2025.

How strong is vTv's cash position after the financing (VTVT)?

Cash was reported at $98.5 million as of September 30, 2025.

What patent protection did vTv (VTVT) secure for cadisegliatin and to when?

A U.S. patent was allowed for crystalline salts/co-crystals of cadisegliatin with term expected through 2041.

What were vTv Therapeutics' (VTVT) Q3 2025 R&D and net loss figures?

Q3 2025 R&D expense was $7.0 million; net loss attributable to shareholders was $8.7 million ($1.08 per basic share).

Will the $80 million financing fund the CATT1 trial for vTv (VTVT)?

The company indicated the proceeds are expected to fund the ongoing CATT1 Phase 3 trial and cadisegliatin development.